Immediate Delivery Versus Expectant Monitoring for Hypertensive Disorders of Pregnancy Between 34 and 37 Weeks of Gestation (HYPITAT-II): An Open-Label, Randomised Controlled Trial

Kim Broekhuijsen*, Gert-Jan van Baaren, Maria G. van Pampus, Wessel Ganzevoort, J. Marko Sikkema, Mallory D. Woiski, Martijn A. Oudijk, Kitty W. M. Bloemenkamp, Hubertina C. J. Scheepers, Henk A. Bremer, Robbert J. P. Rijnders, Aren J. van Loon, Denise A. M. Perquin, Jan M. J. Sporken, Dimitri N. M. Papatsonis, Marloes E. van Huizen, Corla B. Vredevoogd, Jozien T. J. Brons, Mesrure Kaplan, Anton H. van KaamHenk Groen, Martina M. Porath, Paul P. van den Berg, Ben W. J. Mol, Maureen T. M. Franssen, Josje Langenveld

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Patients with hypertensive disorders of pregnancy usually have the 2 treatment options, either immediate delivery or continuing the pregnancy. Although immediately delivery of the placenta is seen as the more definitive of the 2 treatments, it does carry the potentially higher risks of an earlier birth (preterm if
Original languageEnglish
Pages (from-to)605-607
JournalObstetrical & Gynecological Survey
Issue number10
Publication statusPublished - Oct 2015

Cite this